Literature DB >> 15044711

Interferons and interferon inhibitory activity in disease and therapy.

Kailash C Chadha1, Julian L Ambrus, Wlodzimierz Dembinski, Julian L Ambrus.   

Abstract

Interferon (IFN) resistance is an important factor in the pathophysiology of neoplastic disorders, certain viral infections (e.g., AIDS), and autoimmune diseases (e.g., lupus erythematosus and Wegner's granulomatosis). In addition, in some of these disorders, there is also decreased ability to produce IFNs. The capacity of viruses and neoplastic processes to interfere with the IFN system are thought to represent a "virus-against-host" or "cancer-against-host" defense mechanism. Four resistance factors have been identified: 1) release of free IFN-alpha/beta type 1 receptors into the circulation that, at appropriate concentrations, capture and inactivate IFNs; 2) a new IFN inhibitory protein has been isolated and its chemical structure is under study; 3) prostaglandin E2, which is produced by certain tumor cells, inhibits IFN production; and 4) high levels of cAMP phosphodiesterases present, for example in certain tumor cells, reduces cAMP, an important second messenger in IFN synthesis. Studies are under way to reverse these inhibitory effects and to increase endogenous interferon production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044711     DOI: 10.1177/153537020422900402

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  5 in total

1.  Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma.

Authors:  R Ahmad; H Y Qureshi; M El Mabrouk; J Sylvester; M Ahmad; M Zafarullah
Journal:  Ann Rheum Dis       Date:  2006-12-19       Impact factor: 19.103

2.  Cloning, sequencing, heterologous expression, and mechanistic analysis of A-74528 biosynthesis.

Authors:  Kathia Zaleta-Rivera; Louise K Charkoudian; Christian P Ridley; Chaitan Khosla
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

Review 3.  Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.

Authors:  Beata Zahorowska; Philip J Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

4.  Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.

Authors:  Carolina Scagnolari; Petra Duda; Francesca Bagnato; Gabriella De Vito; Alessia Alberelli; Vito Lavolpe; Enrico Girardi; Valentina Durastanti; Maria Trojano; Ludwig Kappos; Guido Antonelli
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

Review 5.  What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Authors:  Katherine A Buzzard; Simon A Broadley; Helmut Butzkueven
Journal:  Int J Mol Sci       Date:  2012-10-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.